ランチョンセミナー17

[LS17] Treatment strategy when we MET NSCLC patients with METex14 skiping mutation―with my clinical experience―

^○Stephen V. Liu (Thoracic Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC)